| 22020 |
Abemaciclib |
Verzenios® |
in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence. |
NCPE Assessment Process complete |
5th June 2024 |
 |
| 20060 |
Atezolizumab in combination with bevacizumab |
Tecentriq® |
For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 22009 |
Avacopan |
Tavneos® |
In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 23075 |
Bimekizumab |
Bimzelx® |
Bimekizumab (Bimzelx®) is indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs |
Rapid Review Complete |
5th June 2024 |
|
| 24014 |
Budesonide |
Jorveza® |
For the treatment of eosinophilic oesophagitis in adults (older than 18 years of age). |
Rapid Review complete |
7th June 2024 |
|
| 22056 |
Buprenorphine |
Buvidal® |
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
Rapid Review complete |
5th June 2024 |
|
| 22003 |
Cefiderocol |
Fetcroja® |
For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
5th June 2024 |
|
| 23063 |
Cytisine |
Citidaron® |
Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
Rapid Review Complete |
5th June 2024 |
|
| 21041 |
Daratumumab |
Darzalex® in combination with cyclophosphamide, bortezomib and dexamethasone |
For the treatment of adult patients with newly diagnosed systemic light chain amyloidosis. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 22039 |
Daratumumab |
Darzalex® |
In combination with lenalidomide (Revlimid®) and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 23076 |
Netarsudil-latanoprost |
Roclanda® |
Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction. |
Rapid Review Complete |
5th June 2024 |
|
| 23050 |
Nivolumab |
Opdivo® |
In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%. |
Rapid Review Complete |
5th June 2024 |
|
| 22027 |
Pembrolizumab |
Keytruda® |
Is indicated in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 23061 |
Risankizumab |
Skyrizi® |
Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 22001 |
Venetoclax |
Venclyxto® |
In combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 23035 |
Vutrisiran |
Amvuttra® |
Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
Rapid Review complete |
5th June 2024 |
|
